Stockreport

Vincerx Pharma Reports Second Quarter 2024 Financial Results

Vincerx Pharma, Inc.  (VINC) 
PDF Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by the end of Q4 2024, and small molecule drug-conjugate (SMD [Read more]